Condition
HMG-CoA Reductase Inhibitor Toxicity
Total Trials
3
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 4 (2)
Trial Status
Active Not Recruiting1
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04636138Not ApplicableActive Not RecruitingPrimary
Pharmacogenomic Modulators of Impaired Exercise Adaptation in Statin Users
NCT04499859Phase 4Recruiting
Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
NCT01013103Phase 4Completed
Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients
Showing all 3 trials